Fundraising Fox
Castle Biosciences
NASDAQ: CSTLFriendswood, US · 3 known investors
Find your way into Castle Biosciences
Sign up to see every warm intro you have to Castle Biosciences
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Castle Biosciences team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Castle Biosciences develops genomic diagnostic tests that use a patient's molecular biology to inform disease management and treatment decisions. Its tests serve healthcare providers and patients across multiple clinical focus areas to guide diagnosis, treatment, and follow-up care.
Founders & leadership
DJ
Derek J. MaetzoldPresident, CEO and DirectorDerek J. Maetzold is Founder, President and CEO of Castle Biosciences, which develops genomic diagnostic tests for cancer management. He previously worked in pharmaceutical development and commercialization, focusing on product development and commercial oversight of pre-approval therapies.
FS
Frank StokesChief Financial OfficerFrank Stokes is Chief Financial Officer of Castle Biosciences, which develops genomic diagnostic tests to inform disease management and treatment decisions.
KO
Kristen OelschlagerChief Operating OfficerShe has held multiple operational leadership roles since the company's founding in 2008, overseeing laboratory operations, information technology, human resources, and regulatory compliance across the organization's growth to a public company with over 900 employees.
TW
Tobin W. JuvenalChief Commercial Officer
Board
MA
Mara AspinallBoard director
DB
JC
Joseph Cook, Jr.Board director
GK
BA
Bonnie AndersonBoard director
Investors · 3
BioBritlisted by BioBritLa Jolla
How we know: the S-1 prospectus · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$54M disclosed across 8 rounds · 2011–2019
▶$10MraisedJul 2019 · 1 investors · BiotechnologyRule 506(b)
▶$10MraisedJul 2019 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Derek MaetzoldExecutive Officer, Director
- Mara AspinallDirector
- Bonnie AndersonDirector
- Daniel M. BradburyDirector
- Joseph C. Cook, IIIDirector
- David Kabakoff, Ph.D.Director
- Frank StokesExecutive Officer
- Bernhard E. SpiessExecutive Officer
- Federico Monzon, M.D., FCAPExecutive Officer
- G. Bradley ColeDirector
- Offering amount
- $20M
- Amount sold
- $10M
- First sale
- Jul 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$11.8MraisedMar 2019 · 65 investors · BiotechnologyRule 506(b)
▶$11.8MraisedMar 2019 · 65 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Federico Monzon, M.D., FCAPExecutive Officer
- Mara AspinallDirector
- G. Bradley ColeDirector
- Joseph C. Cook, Jr.Director
- Derek MaetzoldExecutive Officer, Director
- Daniel M. BradburyDirector
- Bernhard E. SpiessExecutive Officer
- Frank StokesExecutive Officer
- Bonnie AndersonDirector
- David Kabakoff, Ph.D.Director
- Offering amount
- $11.8M
- Amount sold
- $11.8M
- First sale
- Jan 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.1MraisedJun 2018 · 44 investors · BiotechnologyRule 506(b)
▶$5.1MraisedJun 2018 · 44 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Federico Monzon, M.D., FCAPExecutive Officer
- Bernhard E. SpiessExecutive Officer
- Bonnie AndersonDirector
- Mara AspinallDirector
- Joseph C. Cook, Jr.Director
- Derek MaetzoldExecutive Officer, Director
- Daniel M. BradburyDirector
- Frank StokesExecutive Officer
- David Kabakoff, Ph.D.Director
- Offering amount
- $5.3M
- Amount sold
- $5.1M
- First sale
- May 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.5MraisedJan 2018 · 48 investors · BiotechnologyRule 506(b)
▶$5.5MraisedJan 2018 · 48 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Derek MaetzoldExecutive Officer, Director
- Frank StokesExecutive Officer
- David Kabakoff, Ph.D.Director
- Joseph C. Cook, Jr.Director
- Federico Monzon, M.D., FCAPExecutive Officer
- Bonnie AndersonDirector
- Daniel M. BradburyDirector
- Bernhard E. SpiessExecutive Officer
- Mara AspinallDirector
- Offering amount
- $5.5M
- Amount sold
- $5.5M
- First sale
- Jan 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$11.7MraisedJul 2015 · 17 investors · BiotechnologyRule 506(b)
▶$11.7MraisedJul 2015 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mara AspinallDirector
- Daniel BradburyDirector
- Joseph Cook, Jr.Director
- Garheng KongDirector
- Bonnie AndersonDirector
- Derek MaetzoldExecutive Officer, Director
- Offering amount
- $20M
- Amount sold
- $11.7M
- First sale
- Jul 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.5MraisedAug 2014 · 4 investors · BiotechnologyRule 506(b)
▶$7.5MraisedAug 2014 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Joe Cook, Jr.Director
- Derek MaetzoldExecutive Officer, Director
- Daniel BradburyDirector
- Offering amount
- $12M
- Amount sold
- $7.5M
- First sale
- Aug 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.5MraisedAug 2014 · 4 investors · BiotechnologyRule 506(b)
▶$1.5MraisedAug 2014 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Daniel BradburyDirector
- Joe Cook, Jr.Director
- Derek MaetzoldExecutive Officer, Director
- Offering amount
- $1.5M
- Amount sold
- $1.5M
- First sale
- Sep 2011
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1MraisedMay 2014 · 3 investors · BiotechnologyRule 506(b)
▶$1MraisedMay 2014 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Joe Cook, Jr.Director
- Daniel BradburyDirector
- Derek MaetzoldExecutive Officer, Director
- Offering amount
- $1M
- Amount sold
- $1M
- First sale
- Apr 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
American Cancer Society (ACS)The American Cancer Society is a nonprofit organization that provides cancer research updates, screening and prevention guidance, and community engagement opportunities. It serves individuals seeking cancer information and those who want to support cancer research and patient advocacy efforts.
MedscapeMedscape is an online platform providing medical news, clinical information, and continuing education resources to physicians and healthcare professionals globally. The platform offers CME courses, drug and disease information, and patient education across multiple specialties.
CancerresearchukCancer Research UK funds research across discovery, detection, prevention and treatment of cancer to improve patient outcomes and extend survival. It operates as a research funder and scientific organization serving academic and clinical researchers.
Companies working in the same space as Castle Biosciences.
Frequently asked questions
- What does Castle Biosciences do?
- Castle Biosciences develops genomic diagnostic tests that use a patient's molecular biology to inform disease management and treatment decisions. Its tests serve healthcare providers and patients across multiple clinical focus areas to guide diagnosis, treatment, and follow-up care.
- Who founded Castle Biosciences?
- Castle Biosciences was founded by Derek J. Maetzold.
- Who are Castle Biosciences's investors?
- Castle Biosciences's investors include BioBrit, Illumina Ventures, Mountain Group Capital.
- How much funding has Castle Biosciences raised?
- Castle Biosciences has disclosed $54M raised across 8 rounds.
- Where is Castle Biosciences headquartered?
- Castle Biosciences is headquartered in Friendswood, US.